Abstract
Background: Dysregulation of microRNAs (miRNAs) figures prominently in the radio- sensitivity of non-small cell lung cancer (NSCLC). MiR-129-5p can block the development of a variety of tumors. However, whether miR-129-5p modulates radio-sensitivity of NSCLC cells remains unknown.
Objective: This study was aimed to explore the role and the underlying mechanism of miR-129-5p in the radiosensitivity of NSCLC.
Methods: Radio-resistant NSCLC cell lines (A549-R and H1299-R) were constructed using A549 and H1299 cells. Quantitative real-time polymerase chain reaction (qRT-PCR) was employed to quantify miR-129-5p, SRY-box transcription factor 4 (SOX4) mRNA, and RUNX family transcription factor 1 (RUNX1) mRNA expression levels. Cell apoptosis and cell cycle were detected by flow cytometry. Cell counting kit-8 (CCK-8) assay and colony formation experiments were used to measure cell proliferation. γ-H2AX was examined by Western blot to confirm DNA injury. Dual- luciferase reporter experiments were applied to analyze the interactions among miR-129-5p, RUNX1, and SOX4.
Results: In A549-R and H1299-R cells, compared with the wild-type cell lines, miR-129-5p expression was remarkably reduced while SOX4 and RUNX1 expressions were increased. The transfection of miR-129-5p into NSCLC cell lines markedly induced cell apoptosis, DNA injury, cell cycle arrest, and inhibited cell proliferation and colony formation. RUNX1 and SOX4 were validated as target genes of miR-129-5p, and the restoration of RUNX1 or SOX4 could counteract the influence of miR-129-5p on A549-R cells.
Conclusions: MiR-129-5p sensitizes A549-R and H1299-R cells to radiation by targeting RUNX1 and SOX4.
Keywords: NSCLC, miR-129-5p, RUNX1, SOX4, radiosensitivity, qTR-PCR.
Graphical Abstract
[http://dx.doi.org/10.1016/S0140-6736(16)30958-8] [PMID: 27574741]
[http://dx.doi.org/10.1016/j.mayocp.2019.01.013] [PMID: 31378236]
[http://dx.doi.org/10.1038/nature25183] [PMID: 29364287]
[http://dx.doi.org/10.1158/1078-0432.CCR-17-3620] [PMID: 29945993]
[http://dx.doi.org/10.1016/j.bbrc.2018.03.185] [PMID: 29596836]
[http://dx.doi.org/10.3727/096504017X14850182723737] [PMID: 28117028]
[http://dx.doi.org/10.3892/ol.2019.10241] [PMID: 31186804]
[http://dx.doi.org/10.1016/j.bbrc.2017.06.041] [PMID: 28619508]
[http://dx.doi.org/10.1093/jnci/djt356] [PMID: 24309006]
[http://dx.doi.org/10.1242/bio.017608] [PMID: 27029901]
[http://dx.doi.org/10.1038/tpj.2014.21] [PMID: 24980784]
[http://dx.doi.org/10.1002/jcp.29099] [PMID: 31332786]
[http://dx.doi.org/10.2147/CMAR.S168438] [PMID: 30349386]
[http://dx.doi.org/10.1016/j.bbamcr.2018.09.005] [PMID: 30262435]
[http://dx.doi.org/10.12659/MSM.896661] [PMID: 26720492]
[http://dx.doi.org/10.1016/j.biopha.2018.05.123] [PMID: 29857296]
[http://dx.doi.org/10.7150/jca.35410] [PMID: 31949489]
[http://dx.doi.org/10.1186/s12935-019-0977-9] [PMID: 31649488]
[http://dx.doi.org/10.1007/s11255-018-1959-x] [PMID: 30117016]
[http://dx.doi.org/10.1038/s41419-018-0343-1] [PMID: 29531296]
[http://dx.doi.org/10.1002/jcp.27841] [PMID: 30515788]
[http://dx.doi.org/10.3892/or.2018.6209] [PMID: 29328406]
[http://dx.doi.org/10.18632/oncotarget.20433] [PMID: 29245924]
[PMID: 32041394]
[http://dx.doi.org/10.1186/s13046-019-1330-9] [PMID: 31370857]
[http://dx.doi.org/10.3727/096504017X14973124850905] [PMID: 28653608]
[http://dx.doi.org/10.1002/jcp.29122] [PMID: 31385607]